Mitochondria are organelles that are present in all nucleated cells in the body. They have manifold functions but famously generate ATP efficiently through the process of oxidative phosphorylation. This ensures all tissues have an adequate energy supply and underlines the need for a fully functional mitochondrial network. Since mitochondrial biogenesis and maintenance require components from two genetic sources, mitochondrial diseases can result from mutations in either the nuclear or the mitochondrial genome (mtDNA). Enigmatically, mitochondrial disease can affect individuals at any age and in any tissue (Lightowlers et al, 2015). For a subset of mutations, the genotype can be ascribed to a clinical phenotype and a number of mutations are associated with remarkable tissue selectivity (Boczonadi et al, 2018). However, the gene expression pathways governing this tissue-specific presentation are far from clear. In this issue of *EMBO Molecular Medicine*, Sprenger et al (2019) use mouse models to investigate the consequences of deleting a mitochondrial protease, YME1L, in neuronal/glial precursors. The loss causes multiple defects at both cell and tissue level, including a marked fragmentation of the mitochondrial network. Tandem depletion of a second mitochondrial protease, Oma1, successfully restored the mitochondrial connectivity, but did not rescue the ocular defects and caused an earlier onset of neurological dysfunction. Thus, in addition to other findings, the authors conclude that a fragmented mitochondrial network contributes less to the disease phenotype than the disruption of mitochondrial proteostasis.

EMBO Mol Med (2019) 11: e9899
See also: HG Sprenger et al (January 2019)

Mitochondria perform a number of key functions within the cell but are probably most frequently associated with the production of ATP. To assemble much of the chain of enzyme complexes that perform oxidative phosphorylation (OXPHOS) requires coordinated expression and assembly of gene products from both the nuclear and the mitochondrial genome. The catalogue of diseases associated with mitochondrial dysfunction continues to increase, and in many cases, the ubiquity of exome or whole genome sequencing has enabled the identification of the genetic mutations responsible for these pathogenic defects (Taylor et al, 2014). At present, there is no cure for these diseases and treatment, where possible, is currently limited to ameliorating the symptoms of the common presentations, rather than addressing the cause. Work on preventing the transmission of mtDNA mutations is ongoing (Herbert & Turnbull, 2018), but this will not address the problems caused by nuclear-encoded defects. To develop potential therapies for these conditions, which can be varied in presentation, we need to increase our knowledge of the specific consequences of the mutations in a whole organism.

Amongst the different tissue phenotypes, neuronal dysfunction or degradation are common features of mitochondrial disease. However, determining the molecular pathogenesis is challenging. The use of mouse models to address such questions can be very informative. This approach has been adopted by the Langer laboratory to investigate the molecular consequences of mutations in the mitochondrial i-AAA protease, YME1L. The latter is an enzyme that is responsible for the homeostasis both of mitochondrial proteins and phospholipids. It does so mostly by removing proteins that are damaged or have not been correctly assembled into functional complexes and by degrading short-lived lipid transfer proteins (Coenen et al, 2005; Stiburek et al, 2012). Essentially, this prevents the organelle becoming clogged up with dysfunctional debris that would impede mitochondrial function. Additionally, one of the YME1L targets is a dynamin-like GTPase, OPA1, which is crucial for maintenance of mitochondrial dynamics through its involvement in mitochondrial fusion and cristae formation. Pathogenic mutations in YME1L have been identified, and patients harbouring homozygous recessive mutations frequently present with a neuromuscular disorder including movement disturbances and optic atrophy (Hartmann et al, 2016). At a cellular level, the mitochondrial network becomes...
highly fragmented in the affected tissues. This is explained by the stress-activated cleavage of the long isoform of Opa1 (L-Opa1) by a different protease, Oma1, in the Yme1l knockout mouse model. This longer isoform is essential for promoting the fusion of the inner mitochondrial membrane (Ban et al., 2017) and its absence results in a loss of fusion. Interestingly, although fragmented mitochondrial networks can be associated with defects in oxidative phosphorylation, loss of Yme1l in mice caused disrupted mitochondrial morphology and neurological defects independently of any significant deficits in oxidative phosphorylation.

What is the relationship between this change in mitochondrial morphology, eye defects and axonal degeneration with age? Sprenger et al. have used two knockout mouse models to address this question. One mouse line has been generated in which Yme1l is specifically knocked out in neuronal and glial cell precursors. The second line eliminates both YME1L and the IM peptidase, OMA1, which can cleave OPA1 but is usually only activated under stress conditions (Zhang et al., 2014). Sprenger et al have characterised the phenotypes arising from both the individual or combined neuronal-specific knockout mice (Fig 1). In humans, mutations in YME1L cause ocular dysfunction and movement disturbances. The mouse model eliminating Yme1l alone displayed a comparable phenotype with ocular defects including retinal inflammation, cataracts and microphthalmia, a developmental condition where the eyes are abnormally small. This condition is generally associated with increased caspase 9-mediated cell death but in the absence of YME1L there was no apparent stimulation of this pathway, suggesting a different cause for the microphthalmia. Investigating the temporal nature of the neurological impairment identified that the eye-related defects (microphthalmia, cataracts, retinal disorganisation) occurred early on, whilst the axonal and locomotor degeneration only developed later, and were not the consequence of generalised brain atrophy. The tandem knockout of both YME1L and OMA1 restored the dynamic mitochondrial network, but despite this restoration of L-OPA1, not only did the combination of eye defects persist but both the neuroinflammation and axonal degeneration became more severe, with an earlier onset. The combination of models used in these investigations...

Figure 1. A connected mitochondrial network is not sufficient to overcome the physiological defects arising from a loss of YME1L. (A) YME1L activity in wild-type mice maintains a balance of OPA1 forms to retain a dynamic mitochondrial reticulum. (B) Loss of YME1L from neuronal and glial precursors results in a fragmented mitochondrial network, eye defects and late onset of neuroinflammation, with degeneration of dorso-lateral tract-specific axons leading to locomotor impairment. (C) Loss of OMA1 results in stabilisation of L-OPA1 with increased connectivity of mitochondrial tubules, with mild lipid-related symptoms under control conditions (Quiros et al., 2012). (D) When both of the proteases responsible for processing of OPA1 are knocked out, the reticular nature of the mitochondrial network is restored but the defects associated with loss of YME1L alone are retained or even exacerbated.
brings us a little closer to understanding pathogenic mechanisms and that disruption of mitochondrial proteostasis alone can be a driver for disease.

Acknowledgements
This work was supported by The Wellcome Trust (203105/Z/16/Z) and EC Horizon 2020 Marie Curie-Skłodowska ITN REMIX.

Conflict of interest
The authors declare that they have no conflict of interest.

References
Ban T, Ishihara T, Kohno H, Saita S, Ichimura A, Maenaka K, Oka T, Mihara K, Ishihara N (2017) Molecular basis of selective mitochondrial fusion by heterotypic action between OPA1 and cardiolipin. Nat Cell Biol 19: 856–863
Boczonadi V, Jennings MJ, Horvath R (2018) The role of tRNA synthetases in neurological and neuromuscular disorders. FEBS Lett 592: 703–717
Coenen MJ, Smeitink JA, Smeets R, Trijbels FJ, van den Heuvel LP (2005) Mutation detection in four candidate genes (OXA1L, MRS2L, YME1L and MIPEP) for combined deficiencies in the oxidative phosphorylation system. J Inherit Metab Dis 28: 1091–1097
Hartmann B, Wai T, Hu H, MacVicar T, Musante L, Fischer-Zirnsak B, Stenzel W, Graf R, van den Heuvel L, Ropers HH et al (2016) Homozygous YME1L mutation causes mitochondriopathy with optic atrophy and mitochondrial network fragmentation. Elife 5: e16078
Herbert M, Turnbull D (2018) Progress in mitochondrial replacement therapies. Nat Rev Mol Cell Biol 19: 71–72
Lightowlers RN, Taylor RW, Turnbull DM (2015) Mutations causing mitochondrial disease: what is new and what challenges remain? Science 349: 1494–1499
Quiros PM, Ramsay AJ, Sala D, Fernandez-Vizarra E, Rodriguez F, Peinado JR, Fernandez-Garcia MS, Vega JA, Enríquez JA, Zorzano A et al (2012) Loss of mitochondrial protease OMA1 alters processing of the GTPase OPA1 and causes obesity and defective thermogenesis in mice. EMBO J 31: 2117–2133
Sprenger HG, Wani G, Heseling A, König T, Patron M, MacVicar T, Ahola S, Wai T, Barth E, Rugarth El et al (2019) Loss of the mitochondrial i-AAA protease YME1L leads to ocular dysfunction and spinal axonopathy. EMBO Mol Med 11: e9288
Stiburek L, Cesnekova J, Kostkova O, Fornuskova D, Vinsova K, Wenchich L, Houstek J, Zeman J (2012) YME1L controls the accumulation of respiratory chain subunits and is required for apoptotic resistance, cristae morphogenesis, and cell proliferation. Mol Biol Cell 23: 1010–1023
Taylor RW, Pyle A, Griffin H, Blakely EL, Duff J, He L, Smertenko T, Alston CL, Neeve VC, Best A et al (2014) Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA 312: 68–77
Zhang K, Li H, Song Z (2014) Membrane depolarization activates the mitochondrial protease OMA1 by stimulating self-cleavage. EMBO Rep 15: 576–585

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.